February's Biggest Biotech Loser Bounces Back

In the following video, Motley Fool health-care analyst David Williamson takes a look at the dizzying ups and downs of Peregrine Pharmaceuticals (NASDAQ: PPHM  ) . The ongoing saga with the company's leading candidate cancer drug bavituximab has seen shares soar 80% in January, plummet 39% in February, and rally again this month, leaving the stock up 20% overall for the year. David gives investors his take on the drug and where he thinks this wild ride is finally going to end up.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 12, 2013, at 7:37 PM, BSDetector wrote:

    We agree on one line. I too encourage all FOOLS to stay away from this stock. On the other hand I encourage intelligent investors (capable of seeing through hedge fund manipulation) to buy in as they hammer it lower during the next few months. Pay day arrives in July folks.

    Owner since 0.80

  • Report this Comment On March 13, 2013, at 4:03 AM, azurlo wrote:

    Basically you are saying you would need to see significant overall survival benefit in the lung and pancreatic phase II cancer trials to believe in bav. Thus you seem to ignore that in drug development phase II studies aim to confirm drug activity and are always underpowered for OS. Whenever a sign of activıty is seen then a proper phase III trıal, usually wıth a sample size much larger than phase II studies, will be conducted aiming to show a significant OS increase

    Nobody can tell now if the bav phase III trials in lung and pancreatic cancers will be positive in 3-4 years from now, still the planning of these studies seem to be warranted on the basis of the activity shown ın the respective phase II trials. The stock may or not move big in the near future if a partner is found to conduct these trials but, regardelss of this short term development, my understandıng of the data reported so far to is that bav has shown enough activity to be tested in (still risky, as nothing is granted in life) phase III

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2308958, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:21:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
PPHM $0.43 Up +0.00 +0.47%
Peregrine Pharmace… CAPS Rating: **
AEZS $3.45 Up +0.05 +1.47%
Aeterna Zentaris CAPS Rating: *****
CELG $105.83 Down -1.57 -1.46%
Celgene CAPS Rating: *****